Cargando…
Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
This study investigated the immune response and outcome of BNT162b2 vaccination among 12 staff at a hospital in Fukushima, Japan. Blood samples were collected from participants before their first vaccination, with subsequent sampling performed during the participants’ work days for six weeks thereaf...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Fukushima Society of Medical Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071351/ https://www.ncbi.nlm.nih.gov/pubmed/35228456 http://dx.doi.org/10.5387/fms.2021-28 |
_version_ | 1784700828451340288 |
---|---|
author | Kobashi, Yurie Shimazu, Yuzo Kawamura, Takeshi Nishikawa, Yoshitaka Omata, Fumiya Kaneko, Yudai Kodama, Tatsuhiko Tsubokura, Masaharu |
author_facet | Kobashi, Yurie Shimazu, Yuzo Kawamura, Takeshi Nishikawa, Yoshitaka Omata, Fumiya Kaneko, Yudai Kodama, Tatsuhiko Tsubokura, Masaharu |
author_sort | Kobashi, Yurie |
collection | PubMed |
description | This study investigated the immune response and outcome of BNT162b2 vaccination among 12 staff at a hospital in Fukushima, Japan. Blood samples were collected from participants before their first vaccination, with subsequent sampling performed during the participants’ work days for six weeks thereafter. Antibody titers peaked 6-13 days after the second vaccination (days 27-34 after the first), followed by a steady decrease. Six males had significantly lower peak antibody titers than six females (p = 0.016 with t-test); the older six (median age 53 years) had lower antibody titers than the younger six (median age 35 years) but without statistical significance (p value=0.24 with t-test). |
format | Online Article Text |
id | pubmed-9071351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Fukushima Society of Medical Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-90713512022-05-17 Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine Kobashi, Yurie Shimazu, Yuzo Kawamura, Takeshi Nishikawa, Yoshitaka Omata, Fumiya Kaneko, Yudai Kodama, Tatsuhiko Tsubokura, Masaharu Fukushima J Med Sci Brief Report This study investigated the immune response and outcome of BNT162b2 vaccination among 12 staff at a hospital in Fukushima, Japan. Blood samples were collected from participants before their first vaccination, with subsequent sampling performed during the participants’ work days for six weeks thereafter. Antibody titers peaked 6-13 days after the second vaccination (days 27-34 after the first), followed by a steady decrease. Six males had significantly lower peak antibody titers than six females (p = 0.016 with t-test); the older six (median age 53 years) had lower antibody titers than the younger six (median age 35 years) but without statistical significance (p value=0.24 with t-test). The Fukushima Society of Medical Science 2022-02-25 2022 /pmc/articles/PMC9071351/ /pubmed/35228456 http://dx.doi.org/10.5387/fms.2021-28 Text en © 2022 The Fukushima Society of Medical Science https://creativecommons.org/licenses/by-nc-sa/4.0/This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license. https://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Brief Report Kobashi, Yurie Shimazu, Yuzo Kawamura, Takeshi Nishikawa, Yoshitaka Omata, Fumiya Kaneko, Yudai Kodama, Tatsuhiko Tsubokura, Masaharu Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine |
title | Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine |
title_full | Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine |
title_fullStr | Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine |
title_full_unstemmed | Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine |
title_short | Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine |
title_sort | peak igg antibody titers against sars-cov-2 spike protein following immunization with the pfizer/biontech bnt162b2 vaccine |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071351/ https://www.ncbi.nlm.nih.gov/pubmed/35228456 http://dx.doi.org/10.5387/fms.2021-28 |
work_keys_str_mv | AT kobashiyurie peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine AT shimazuyuzo peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine AT kawamuratakeshi peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine AT nishikawayoshitaka peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine AT omatafumiya peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine AT kanekoyudai peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine AT kodamatatsuhiko peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine AT tsubokuramasaharu peakiggantibodytitersagainstsarscov2spikeproteinfollowingimmunizationwiththepfizerbiontechbnt162b2vaccine |